Literature DB >> 28119848

Acute Cerebral Infarction as a Rare Thrombotic Event in Myelodysplastic Syndrome: A Case Report.

Hyun Woo Bae1, Hyun Dong Kim1, Sung Won Choi1, Nami Han1, Mi Ja Eom1.   

Abstract

Myelodysplastic syndrome (MDS) is a bone marrow failure syndrome characterized by cytopenia that results in high risks of infection and bleeding. However, there are few reports of cerebral infarction in MDS. We reported a 72-year-old female with MDS who developed acute cerebral infarction. Clinical history of the patient revealed no definite risk factors for stroke except diabetes mellitus and dyslipidemia that was well controlled. This case represented the rare occurrence of arterial thrombosis causing acute cerebral infarction in MDS, which may be due to complex chromosomal abnormality and inflammatory processes.

Entities:  

Keywords:  Myelodysplastic syndromes; Stroke; Thrombosis

Year:  2016        PMID: 28119848      PMCID: PMC5256339          DOI: 10.5535/arm.2016.40.6.1144

Source DB:  PubMed          Journal:  Ann Rehabil Med        ISSN: 2234-0645


  8 in total

Review 1.  Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet's syndrome.

Authors:  S Kimura; J Kuroda; T Akaogi; H Hayashi; Y Kobayashi; M Kondo
Journal:  Leuk Lymphoma       Date:  2001-06

Review 2.  10. Older Adults.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

3.  Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.

Authors:  Sheila Weiss Smith; Masayo Sato; Steven D Gore; Maria R Baer; Xuehua Ke; Diane McNally; Amy Davidoff
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 4.  The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).

Authors:  John M Bennett; Peter A Kouides; Stephen J Forman
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.

Authors:  Guibin Chen; Weihua Zeng; Akira Miyazato; Eric Billings; Jaroslaw P Maciejewski; Sachiko Kajigaya; Elaine M Sloand; Neal S Young
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

6.  Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.

Authors:  R B D'Agostino; P A Wolf; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

7.  Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome.

Authors:  Hui-Chi Hsu; Yuan-Ming Lee; Wen-Hui Tsai; Mei-Lan Jiang; Chau-Hung Ho; Chi-Kuan Ho; Sheng-Yuan Wang
Journal:  Oncology       Date:  2002       Impact factor: 2.935

8.  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.

Authors:  Xionghu Yang; Nancy A Brandenburg; John Freeman; Maria Luisa Salomon; Jerome B Zeldis; Robert D Knight; Robert Bwire
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

  8 in total
  2 in total

1.  Early Path Nursing on Neurological Function Recovery of Cerebral Infarction.

Authors:  Ling Chen; Zhena Han; Junjie Gu
Journal:  Transl Neurosci       Date:  2019-10-02       Impact factor: 1.757

2.  Observation of the Effect of Nursing BPR on Thrombolytic Efficacy and Prognosis of Patients with Cerebral Infarction Based on CT Images.

Authors:  Shaomin Wang; Xiao Miao; Guanghui Zhang; Dandan Li; Li Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-09-14       Impact factor: 3.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.